(Q34030140)

30 July 2017

1 reference

title

Abacavir: a review of its clinical potential in patients with HIV infection (English)

1 reference

30 July 2017

1 reference

P S Hervey

1

1 reference

PubMed ID

10983741

30 July 2017

C M Perry

series ordinal

2

1 reference

30 July 2017

1 August 2000

1 reference

30 July 2017

1 reference

30 July 2017

60

1 reference

30 July 2017

2

1 reference

30 July 2017

447-479

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200060020-00015

30 July 2017

0 references

cites work

A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 I

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200060020-00015

Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

21 January 2018

1 reference

12 December 2020

Abacavir rechallenge has to be avoided in case of hypersensitivity reaction

1 reference

12 December 2020

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome

1 reference

12 December 2020

Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study

1 reference

12 December 2020

Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults

1 reference

12 December 2020

Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team

1 reference

12 December 2020

Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection

1 reference

12 December 2020

Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection

1 reference

12 December 2020

Anaphylaxis after rechallenge with abacavir

1 reference

12 December 2020

Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity

1 reference

12 December 2020

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

1 reference

12 December 2020

Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy

1 reference

12 December 2020

Genotypic and phenotypic characterization of HIV-1 patients with primary infection

1 reference

12 December 2020

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

1 reference

12 December 2020

Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.

1 reference

12 December 2020

Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro

1 reference

12 December 2020

HIV-protease inhibitors

1 reference

12 December 2020

A risk-benefit assessment of HIV protease inhibitors

1 reference

12 December 2020

Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults

1 reference

12 December 2020

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.

1 reference

12 December 2020

Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir

1 reference

12 December 2020

The development of resistance of HIV-1 to zalcitabine

1 reference

12 December 2020

Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development

1 reference

12 December 2020

Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects

1 reference

12 December 2020

Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease

1 reference

12 December 2020

A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team

1 reference

12 December 2020

Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89

1 reference

12 December 2020

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects

1 reference

12 December 2020

10.2165/00003495-200060020-00015

Identifiers

DOI

1 reference

PubMed ID

10983741

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

10983741